|
1
|
Ma L, Xie Y, Ke S, Liu D, Wang L, Wang L
and Liu L: Levothyroxine dose prediction post-thyroidectomy for
differentiated thyroid carcinoma. Front Endocrinol (Lausanne).
16(1727681)2025.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Zhu Q, Liu J, Hu J and Zhang Y: The
epidemiological landscape of thyroid cancer and estimates of
overdiagnosis in China: A population-based study. Thyroid.
35:307–320. 2025.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Gao N, Han J, Sun X, Yu J, Huang J, Liu R,
Tang YL and Nie C: Erianin induces apoptosis of thyroid cancer
cells via TNF signaling pathway. Eur J Pharmacol.
1006(178167)2025.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Li C, Li Q, Shi X, Han S, Song X, Li X and
Zhuang X: Papillary thyroid microcarcinoma and papillary thyroid
carcinoma: Clinical characteristics and stratification of treatment
strategies. PLoS One. 20(e0327423)2025.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Liang L, Chen Z, Lei D, Mo C, Lan D, Ke J,
Wang W, Yang Z, Guo X, Chen D, et al: APG-115 induces
SLC7A11-mediated ferroptosis and upregulates PD-L1 expression in
thyroid cancer. ACS Omega. 10:31099–31107. 2025.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Elyamany AM, Abdel Haleem RT, Soliman NA,
Mahdi L, Ahmed HMA and Abdelwahab KH: Expression of long non-coding
RNA-NEAT-1 in papillary thyroid carcinoma in relation to
immunohistochemical expression of CD8 and PD-L1 as indicators of
tumor immune microenvironment. Asian Pac J Cancer Prev.
26:3093–3101. 2025.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Xue Y, Zhuang Y and Chen S: Dynamic
survival outcomes of the tall-cell variant of papillary thyroid
carcinoma patients after surgery. Front Endocrinol (Lausanne).
16(1517907)2025.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Toloza FJK, Gubbi S and Klubo-Gwiezdzinska
J: Trends in survival and factors associated with survival in
primary thyroid lymphoma: A SEER-based analysis (1975-2021).
Thyroid. 35:1074–1082. 2025.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Gu Y, Yu M, Deng J and Lai Y: Preoperative
circulating tumor cells level is associated with lymph node
metastasis in patients with unifocal papillary thyroid carcinoma.
World J Surg Oncol. 23(47)2025.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Shen P, Yang Z, Sun J, Wang Y, Qiu C, Wang
Y, Ren Y, Liu S, Cai W, Lu H and Yao S: Explainable multimodal deep
learning for predicting thyroid cancer lateral lymph node
metastasis using ultrasound imaging. Nat Commun.
16(7052)2025.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Liu Y, Huang S, Li X, Tian T and Huang R:
Therapeutic efficacies of remnant ablation and radioiodine adjuvant
therapy in differentiated thyroid cancer. Endocrine. 87:734–743.
2025.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Feng Y, Xiao A, Xing C, Dai Q, Liu X, Liu
J and Feng L: Elevated thyroid-stimulating hormone levels,
independent of Hashimoto's thyroiditis, increase thyroid cancer
risk: Insights from genetic and clinical evidence. Endocrine.
88:175–184. 2025.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Pishdad R and Ahmadi S:
Thyroid-stimulating hormone (TSH) suppression therapy in thyroid
cancer: Balancing benefits and harms. Endocr Pract. 32:401–405.
2026.PubMed/NCBI View Article : Google Scholar
|
|
14
|
He Z, Wang C, Liu C, Zhang K, Wang J, Wang
X, Zhang Y and Chen L: Limited value of genetic profiling in
guiding radioiodine therapy for metastatic differentiated thyroid
cancer. Endocr Relat Cancer. 32(e240298)2025.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Ricarte-Filho JC, Caperton CO, Isaza A,
Massoll NA and Franco AT: Macrophage abundance in oncocytic thyroid
cancer is associated with PD-L1 expression. Endocr Oncol.
5(e250026)2025.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Piermattei A, Migliara G, Feraco A, Bruno
C, Cioni L, Zhang Q, Padial-Urtueta B, Merenda E, Fadda G,
Raffaelli M, et al: Evaluation of PD-L1, TERT promoter mutations,
and BRAFV600E mutation in poorly differentiated, differentiated
high grade thyroid carcinoma and anaplastic carcinoma of the
thyroid: Our institutional experience. Virchows Arch. 487:605–618.
2025.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Forma A, Kłodnicka K, Pająk W, Flieger J,
Teresińska B, Januszewski J and Baj J: Thyroid cancer:
Epidemiology, classification, risk factors, diagnostic and
prognostic markers, and current treatment strategies. Int J Mol
Sci. 26(5173)2025.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Li X, Gao S, Shan C, Zhang Q, Tan Y, Yu X
and Yu J: Advances in PD-1/PD-L1 pathway inhibitors in the
treatment of thyroid cancer: Mechanisms and clinical therapeutic
perspectives. Front Immunol. 16(1643421)2025.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Zhang J, Bu X, Wang H, Zhu Y, Geng Y,
Nihira NT, Tan Y, Ci Y, Wu F, Dai X, et al: Cyclin D-CDK4 kinase
destabilizes PD-L1 via cullin 3-SPOP to control cancer immune
surveillance. Nature. 553:91–95. 2018.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Wang Y, Ma X, Ma J, Li J, Lin Z, Gao W,
Gong P and Dai P: Thyroid dysfunction as a predictor of PD- 1/PD-L1
inhibitor efficacy in advanced lung cancer. BMC Cancer.
25(791)2025.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Yan X, Lv Q, Wu J, Fang J, Peng L and Zhao
X: The efficacy and immune-mediated safety of PD-1/PD-L1 combined
with neoadjuvant chemotherapy in triple-negative breast cancer: A
meta-analysis. Front Oncol. 15(1635418)2025.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Liotti F, Kumar N, Prevete N, Marotta M,
Sorriento D, Ieranò C, Ronchi A, Marino FZ, Moretti S, Colella R,
et al: PD-1 blockade delays tumor growth by inhibiting an intrinsic
SHP2/Ras/MAPK signalling in thyroid cancer cells. J Exp Clin Cancer
Res. 40(22)2021.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Lin J, Qiu Y, Zheng X, Dai Y and Xu T: The
miR-199a-5p/PD-L1 axis regulates cell proliferation, migration and
invasion in follicular thyroid carcinoma. BMC Cancer.
22(756)2022.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Banerjee S, Nahar U, Dahiya D, Mukherjee
S, Dey P, Gupta R, Radotra B, Sachdeva N, Sood A, Bhadada SK and
Bhansali A: Role of cytotoxic T cells and PD-1 immune checkpoint
pathway in papillary thyroid carcinoma. Front Endocrinol
(Lausanne). 13(931647)2022.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Banerjee S, Nahar U, Dahiya D, Gupta R,
Mukherjee S, Sachdeva N, Sood A, Dey P, Radotra B and Bhansali A:
IL-17 A correlates with disease progression in papillary thyroid
carcinoma. Diagn Pathol. 18(93)2023.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Dong H, Strome SE, Salomao DR, Tamura H,
Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, et al:
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential
mechanism of immune evasion. Nat Med. 8:793–800. 2002.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Cheng W, Kang K, Zhao A and Wu Y: Dual
blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung
cancer. J Hematol Oncol. 17(54)2024.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Han Y, Koehler VF, Nagarajah J, Schmohl
KA, Stauss C, Schwenk N, Spellerberg R, Kitzberger C, Kumbrink J,
Zach C, et al: TGF-β1-based restoration of sodium iodide symporter
expression in radioiodine-refractory differentiated thyroid cancer
via engineered MSCs. Mol Ther. 33:6130–6145. 2025.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Xiang J, Lv N, Yin S, Zhao T, Liu F, Cheng
L, Liu F and Kuang J: TGF-β induces EMT in thyroid cancer cells by
regulating transcription factors. Thyroid Res.
18(25)2025.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Garcia-Rendueles AR, Rodrigues JS,
Garcia-Rendueles MER, Suarez-Fariña M, Perez-Romero S, Barreiro F,
Bernabeu I, Rodriguez-Garcia J, Fugazzola L, Sakai T, et al:
Rewiring of the apoptotic TGF-β-SMAD/NFκB pathway through an
oncogenic function of p27 in human papillary thyroid cancer.
Oncogene. 36:652–666. 2017.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Zhao JJ, Hao S, Wang LL, Hu CY, Zhang S,
Guo LJ, Zhang G, Gao B, Jiang Y, Tian WG and Luo DL: Long
non-coding RNA ANRIL promotes the invasion and metastasis of
thyroid cancer cells through TGF-β/Smad signaling pathway.
Oncotarget. 7:57903–57918. 2016.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Lin Q, Qi Q, Hou S, Chen Z, Jiang N, Zhang
L and Lin C: Activation of the TGF-β1/Smad signaling by KIF2C
contributes to the malignant phenotype of thyroid carcinoma cells.
Tissue Cell. 73(101655)2021.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Ma S, Wang Q, Ma X, Wu L, Guo F, Ji H, Liu
F, Zhao Y and Qin G: FoxP3 in papillary thyroid carcinoma induces
NIS repression through activation of the TGF-β1/Smad signaling
pathway. Tumour Biol. 37:989–998. 2016.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Jung CK, Bychkov A and Kakudo K: Update
from the 2022 World Health Organization classification of thyroid
tumors: A standardized diagnostic approach. Endocrinol Metab
(Seoul). 37:703–718. 2022.PubMed/NCBI View Article : Google Scholar
|
|
35
|
van Staveren WCG, Solís DW, Delys L,
Duprez L, Andry G, Franc B, Thomas G, Libert F, Dumont JE, Detours
V and Maenhaut C: Human thyroid tumor cell lines derived from
different tumor types present a common dedifferentiated phenotype.
Cancer Res. 67:8113–8120. 2007.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Saiselet M, Floor S, Tarabichi M, Dom G,
Hébrant A, van Staveren WC and Maenhaut C: Thyroid cancer cell
lines: An overview. Front Endocrinol (Lausanne).
3(133)2012.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Shen DHY, Chan HP, Tsai FR, Chiu YL, Liang
TJ, She Y, Liu AC, Yeh HY, Tsai KW and Li SC: MDM2 Knockdown
reduces the oncogenic activities and enhances NIS protein abundance
in papillary thyroid cancer. Cancer Genomics Proteomics.
22:444–457. 2025.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Bhatti MZ, Pan L, Wang T, Shi P and Li L:
REGγ potentiates TGF-β/Smad signal dependent epithelial-mesenchymal
transition in thyroid cancer cells. Cell Signal.
64(109412)2019.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Jiao C, Li L, Zhang P, Zhang L, Li K, Fang
R, Yuan L, Shi K, Pan L, Guo Q, et al: REGγ ablation impedes
dedifferentiation of anaplastic thyroid carcinoma and accentuates
radio-therapeutic response by regulating the Smad7-TGF-β pathway.
Cell Death Differ. 27:497–508. 2020.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Riesco-Eizaguirre G, Rodríguez I, De la
Vieja A, Costamagna E, Carrasco N, Nistal M and Santisteban P: The
BRAFV600E oncogene induces transforming growth factor beta
secretion leading to sodium iodide symporter repression and
increased malignancy in thyroid cancer. Cancer Res. 69:8317–8325.
2009.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Azouzi N, Cailloux J, Cazarin JM, Knauf
JA, Cracchiolo J, Al Ghuzlan A, Hartl D, Polak M, Carré A, El
Mzibri M, et al: NADPH oxidase NOX4 is a critical mediator of
BRAFV600E-induced downregulation of the sodium/iodide
symporter in papillary thyroid carcinomas. Antioxid Redox Signal.
26:864–877. 2017.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Yu H, Pardoll D and Jove R: STATs in
cancer inflammation and immunity: A leading role for STAT3. Nat Rev
Cancer. 9:798–809. 2009.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Lee KY, Ito K, Hayashi R, Jazrawi EPI,
Barnes PJ and Adcock IM: NF-kappaB and activator protein 1 response
elements and the role of histone modifications in IL-1beta-induced
TGF-beta1 gene transcription. J Immunol. 176:603–615.
2006.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Ning Q, Liu J, Liu S, Zou Q, Li K and Li
Z: TRx0237 induces apoptosis and enhances anti-PD-1
immunotherapeutic efficacy in anaplastic thyroid cancer. Int
Immunopharmacol. 155(114610)2025.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Eloy C, Santos J, Cameselle-Teijeiro J,
Soares P and Sobrinho-Simões M: TGF-beta/Smad pathway and BRAF
mutation play different roles in circumscribed and infiltrative
papillary thyroid carcinoma. Virchows Arch. 460:587–600.
2012.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Bullock KK and Richmond A: Beyond
anti-PD-1/PD-L1: Improving immune checkpoint inhibitor responses in
triple-negative breast cancer. Cancers (Basel).
16(2189)2024.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Quan Z, Yang Y, Zheng H, Zhan Y, Luo J,
Ning Y and Fan S: Clinical implications of the interaction between
PD-1/PD-L1 and PI3K/AKT/mTOR pathway in progression and treatment
of non-small cell lung cancer. J Cancer. 13:3434–3443.
2022.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Zhuang J, Huang B, Li J, Wang Y, Xu Y, Yu
X, Shen H and Gao W: Upregulation of FLT1 activates the
TGF-β1/Smad3 pathway to promote iodide resistance in thyroid
cancer. Cancer Treat Res Commun. 45(100991)2025.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Yan Z, Yangyanqiu W, Shuwen H, Jing M,
Haihong L, Gong C, Yin J, Qing Z and Weili G: Downregulation of
Rap1GAP expression activates the TGF-β/Smad3 pathway to inhibit the
expression of sodium/iodine transporter in papillary thyroid
carcinoma cells. Biomed Res Int. 2021(6840642)2021.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Yao X, Tu Y, Xu Y, Guo Y, Yao F and Zhang
X: Endoplasmic reticulum stress-induced exosomal miR-27a-3p
promotes immune escape in breast cancer via regulating PD-L1
expression in macrophages. J Cell Mol Med. 24:9560–9573.
2020.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Qiu X, Zhu J, Sun Y, Fan K, Yang DR, Li G,
Yang G and Chang C: TR4 nuclear receptor increases prostate cancer
invasion via decreasing the miR-373-3p expression to alter
TGFβR2/p-Smad3 signals. Oncotarget. 6:15397–15409. 2015.PubMed/NCBI View Article : Google Scholar
|
